{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:40:45Z","timestamp":1792453245660,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.critrevonc.2025.104783","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:16:16Z","timestamp":1748344576000},"page":"104783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacy"],"prefix":"10.1016","volume":"213","author":[{"given":"Sara Al","family":"Dali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman F.","family":"Al-Mashdali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Kalfah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shehab F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"ement 2","key":"10.1016\/j.critrevonc.2025.104783_bib1","doi-asserted-by":"crossref","first-page":"LBA-5","DOI":"10.1182\/blood-2023-192042","article-title":"Revumenib Monotherapy in Patients with Relapsed\/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study","volume":"142","author":"Aldoss","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104783_bib2","unstructured":"Aldoss, I. (2024) \u2018Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R\/R) <em>KMT2Ar<\u202f\/em>\u202fAcute Leukemia\u2019, in. 66th ASH Annual Meeting, ASH. Available at: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper194384.html (Accessed: 2 January 2025)."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104783_bib3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-024-01573-2","article-title":"Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH Annual Meeting","volume":"17","author":"An","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104783_bib4","unstructured":"Armstrong, M. (no date) Kura leaves some combo questions unanswered, ApexOnco. Available at: https:\/\/www.oncologypipeline.com\/apexonco\/https%3A%2F%2Fwww.oncologypipeline.com%2Fapexonco%2Fkura-leaves-some-combo-questions-unanswered (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib5","unstructured":"Beat A.M.L., LLC (2024) A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial). Clinical trial registration NCT03013998. clinicaltrials.gov. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03013998 (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib6","unstructured":"Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R\/R) Acute Myeloid Leukemia (AML) at the 2023 ASH | Biomea Fusion (2023). Available at: https:\/\/investors.biomeafusion.com\/news-releases\/news-release-details\/biomea-fusion-presents-achievement-minimal-residual-disease\/ (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib7","unstructured":"Borate, U. (2024) \u2018Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with <em>NPM1<\u202f\/Em>\u202fMutations or <em>KMT2A <\u202f\/Em>rearrangements from the Beat AML Master Clinical Trial\u2019, in. 66th ASH Annual Meeting, ASH. Available at: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper211261.html (Accessed: 2 January 2025)."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104783_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/hematolrep16020024","article-title":"A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia","volume":"16","author":"Candoni","year":"2024","journal-title":"Hematol. Rep."},{"key":"10.1016\/j.critrevonc.2025.104783_bib9","unstructured":"Children\u2019s Oncology Group (2024) A Phase 2 Study of Revumenib (SNDX-5613) in Combination With Chemotherapy for Patients With Relapsed or Refractory KMT2A-Rearranged Infant Leukemia. Clinical trial registration NCT05761171. clinicaltrials.gov. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05761171 (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib10","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1182\/blood-2021-147856","article-title":"Phase 1\/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients (pts) with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement or Nucleophosmin 1 (NPM1) Mutation","volume":"138","author":"Daver","year":"2021","journal-title":"Blood"},{"issue":"16_","key":"10.1016\/j.critrevonc.2025.104783_bib11","article-title":"Phase 1\/2, open-label, dose-escalation, dose-expansion study of menin inhibitor DSP-5336 in adult patients with acute leukemia with and without mixed-lineage leukemia (MLL)-rearrangement (r) or nucleophosmin 1 (NPM1) mutation (m).","volume":"40","author":"Daver","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"10393","key":"10.1016\/j.critrevonc.2025.104783_bib12","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet (Lond., Engl. )"},{"key":"10.1016\/j.critrevonc.2025.104783_bib13","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104783_bib14","unstructured":"EHA (2024) EHA 2024 \u2013 Syndax sets up another menin inhibitor battle, ApexOnco. Available at: https:\/\/www.oncologypipeline.com\/apexonco\/https%3A%2F%2Fwww.oncologypipeline.com%2Fapexonco%2Feha-2024-syndax-sets-another-menin-inhibitor-battle (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib15","doi-asserted-by":"crossref","unstructured":"Fathi, A. (2024) Ziftomenib Combined with Venetoclax\/Azacitidine in Relapsed\/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET\u2011007, in. 66th ASH Annual Meeting, ASH. Available at: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper199170.html (Accessed: 10 January 2025).","DOI":"10.1182\/blood-2024-199170"},{"issue":". S1","key":"10.1016\/j.critrevonc.2025.104783_bib16","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2023-190475","article-title":"Komet-008: A Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-Rearranged or NPM1-Mutant Relapsed\/Refractory Acute Myeloid Leukemia","volume":"142","author":"Goldberg","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104783_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.critrevonc.2025.104783_bib18","doi-asserted-by":"crossref","unstructured":"Issa, G. (2024) Phase I\/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine\/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R\/R AML, in. 66th ASH Annual Meeting, ASH. Available at: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper204375.html (Accessed: 2 January 2025).","DOI":"10.1182\/blood-2024-204375"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104783_bib19","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","article-title":"Therapeutic implications of menin inhibition in acute leukemias","volume":"35","author":"Issa","year":"2021","journal-title":"Leukemia"},{"issue":"ement 1","key":"10.1016\/j.critrevonc.2025.104783_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2023-182337","article-title":"Early Results of the Phase I\/II Study Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine\/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)","volume":"142","author":"Issa","year":"2023","journal-title":"Blood"},{"issue":"7954","key":"10.1016\/j.critrevonc.2025.104783_bib21","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104783_bib22","doi-asserted-by":"crossref","unstructured":"Jabbour, E. (2023) A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed\/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations, in. 65th ASH Annual Meeting & Exposition, ASH. Available at: https:\/\/ash.confex.com\/ash\/2023\/webprogram\/Paper172422.html (Accessed: 2 January 2025).","DOI":"10.1182\/blood-2023-172422"},{"key":"10.1016\/j.critrevonc.2025.104783_bib23","unstructured":"Janssen Research & Development, LLC (2024) A Phase 1&2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia. Clinical trial registration NCT04811560. clinicaltrials.gov. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04811560 (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib24","unstructured":"Journalonko (2024a) A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies, Journalonko.de. Available at: https:\/\/www.journalonko.de\/studien\/details\/nct05453903 (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib25","unstructured":"Journalonko (2024b) A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed\/Refractory Acute Leukemias, Journalonko.de. Available at: https:\/\/www.journalonko.de\/studien\/details\/nct05521087 (Accessed: 2 January 2025)."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104783_bib26","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104783_bib27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104783_bib28","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia","volume":"6","author":"K\u00fchn","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104783_bib29","unstructured":"Kura Oncology, Inc. (2024) A Phase 1\/2 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clinical trial registration NCT04067336. clinicaltrials.gov. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04067336 (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib30","unstructured":"Kura Oncology, Inc. (2024a) A Phase 1&2; First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia. Clinical trial registration NCT04067336. clinicaltrials.gov. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04067336 (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib31","unstructured":"Kura Oncology, Inc (2024b) A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax\/Azacitidine, Venetoclax, or 7+\u202f3 in Patients with AML. Clinical trial registration NCT05735184. clinicaltrials.gov. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05735184 (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib32","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1182\/blood-2023-173149","article-title":"Covalent Menin Inhibitor Bmf-219 in Patients with Relapsed or Refractory (R\/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the Covalent-101 Study","volume":"142","author":"Lancet","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104783_bib33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-024-01632-8","article-title":"Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead","volume":"17","author":"Nadiminti","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104783_bib34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12935-023-02877-y","article-title":"A novel Menin-MLL1 inhibitor, DS-1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1","volume":"23","author":"Numata","year":"2023","journal-title":"Cancer Cell Int."},{"issue":"7954","key":"10.1016\/j.critrevonc.2025.104783_bib35","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.critrevonc.2025.104783_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.35332","article-title":"Targeting the Menin\u2013KMT2A interaction in leukemia: Lessons learned and future directions","author":"Perner","year":"2025","journal-title":"Int. J. Cancer [Prepr. ]"},{"key":"10.1016\/j.critrevonc.2025.104783_bib37","unstructured":"Recher, C. (2024) \u2018Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with <em>KMT2Ar<\u202f\/Em>\u202for <em>NPM1<\u202f\/Em>\u202fAlterations\u2019, in. 66th ASH Annual Meeting, ASH. Available at: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper207072.html (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib38","unstructured":"Rosa, K. (2022) Clinical Activity and Tolerable Safety Shown with Ziftomenib in R\/R AML, Targeted Oncology. Available at: https:\/\/www.targetedonc.com\/view\/clinical-activity-and-tolerabel-safety-shown-with-ziftomenib-in-r-r-aml (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib39","unstructured":"Sava, J. (2023) Phase 2 KOMET-001 Trial of Ziftomenib Begins Dosing Patients With NPM1-Mutant AML, Targeted Oncology. Available at: https:\/\/www.targetedonc.com\/view\/phase-2-komet-001-trial-of-ziftomenib-begins-dosing-patients-with-npm1-mutant-aml (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib40","unstructured":"Sava, J. (2024) FDA Fast Tracks DSP-5336 in NPM1\/KMT2A+\u202fAcute Leukemia, Targeted Oncology. Available at: https:\/\/www.targetedonc.com\/view\/fda-fast-tracks-dsp-5336-in-npm1-kmt2a-acute-leukemia (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib41","unstructured":"Searle, E. (2024) \u2018Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed\/Refractory Acute Leukemia Patients with <em>KMT2A<\u202f\/Em>\u202fand <em>NPM1<\u202f\/Em>\u202fAlterations\u2019, in. 66th ASH Annual Meeting, ASH. Available at: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper207106.html (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib42","unstructured":"Syndax Pharmaceuticals (2024a) A Phase 1\/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX-5613 in Patients With Relapsed\/Refractory Leukemias, Including Those Harboring an MLL\/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation. Clinical trial registration NCT04065399. clinicaltrials.gov. Available at: https:\/\/clinicaltrials.gov\/study\/NCT04065399 (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib43","unstructured":"Syndax Pharmaceuticals (2024b) AUGMENT-102: A Phase 1, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability and Preliminary Anti-Leukemic Activity of SNDX-5613 in Combination With Chemotherapy in Patients With Relapsed\/Refractory Leukemias Harboring Alterations in KMT2A\/MLL, Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes. Clinical trial registration NCT05326516. clinicaltrials.gov. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05326516 (Accessed: 2 January 2025)."},{"key":"10.1016\/j.critrevonc.2025.104783_bib44","unstructured":"Syndax Pharmaceuticals (no date) Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials | Syndax Pharmaceuticals, Inc. Available at: https:\/\/ir.syndax.com\/news-releases\/news-release-details\/syndax-announces-positive-data-revumenib-patients-acute (Accessed: 2 January 2025)."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104783_bib45","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3390\/biomedicines11020641","article-title":"Targeted Therapy Development in Acute Myeloid Leukemia","volume":"11","author":"Totiger","year":"2023","journal-title":"Biomedicines"},{"issue":"6477","key":"10.1016\/j.critrevonc.2025.104783_bib46","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Sci. (N. Y., N. Y. )"},{"key":"10.1016\/j.critrevonc.2025.104783_bib47","unstructured":"UCSF (2024) UCSF Leukemia Trial: Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia. Available at: https:\/\/clinicaltrials.ucsf.edu\/trial\/NCT05761171 (Accessed: 2 January 2025)."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104783_bib48","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/MOH.0000000000000796","article-title":"The future of HOXA- expressing leukemias: Menin inhibitor response and resistance","volume":"31","author":"Wenge","year":"2024","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104783_bib49","doi-asserted-by":"crossref","first-page":"S308","DOI":"10.1016\/S2152-2650(23)01074-1","volume":"23","author":"Zeidan","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.critrevonc.2025.104783_bib50","doi-asserted-by":"crossref","unstructured":"Zeidan, A. (2024) \u2018Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed <em>NPM1-<\u202f\/em>m or <em>KMT2A<\u202f\/em>\u202f-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007\u2019, in. 66th ASH Annual Meeting, ASH. Available at: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper198218.html (Accessed: 2 January 2025).","DOI":"10.1182\/blood-2024-198218"},{"key":"10.1016\/j.critrevonc.2025.104783_bib51","unstructured":"Zeidner, J. (2024) \u2018Phase 1 Results: First-in-Human Phase 1\/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia\u2019, in. 66th ASH Annual Meeting, ASH. Available at: https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper194827.html (Accessed: 2 January 2025)."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825001714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T20:44:52Z","timestamp":1756154692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825001714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":51,"alternative-id":["S1040842825001714"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104783","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacy","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104783"}}